Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Petros Pharmaceuticals ( (PTPI) ) just unveiled an update.
On March 31, 2025, Petros Pharmaceuticals‘ subsidiary, Metuchen Pharmaceuticals, terminated its license agreement with Vivus, Inc., ceasing rights to Stendra® avanafil in multiple territories. This led to the cessation of development and commercialization of Stendra® and the transfer of related assets to Vivus. Additionally, on June 16, 2025, Petros Pharmaceuticals assigned all assets of its subsidiaries to a third-party fiduciary as part of a judicial insolvency procedure, resulting in the classification of these operations as discontinued and the deconsolidation of assets from its balance sheet.
The most recent analyst rating on (PTPI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Petros Pharmaceuticals stock, see the PTPI Stock Forecast page.
More about Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the commercialization and exploitation of pharmaceutical products. A key product was Stendra® avanafil, which was licensed through a terminated agreement with Vivus, Inc.
Average Trading Volume: 12,269,711
Technical Sentiment Signal: Sell
Current Market Cap: $841.3K
For a thorough assessment of PTPI stock, go to TipRanks’ Stock Analysis page.